Treace Medical Concepts, Inc. (TMCI) stock
TMCINasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/3031% below fair value
$4.44+0.02 (+0.45%)
Close on Nov 17, 2026Market cap $288.75MP/E –Yield –
Treace Medical Concepts r&d expenses
Research and development expenses are spending on new products and technology.
Treace Medical Concepts's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.22M, down 14.2% year over year. For fiscal 2025 it was $20.28M, down 1.5% from the year before. The highest annual figure on record is $20.59M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.28M | -1.5% |
| FY2024 | Dec 31, 2024 | $20.59M | +33.3% |
| FY2023 | Dec 31, 2023 | $15.44M | +13.7% |
| FY2022 | Dec 31, 2022 | $13.58M | +33.1% |
| FY2021 | Dec 31, 2021 | $10.20M | +74.5% |
| FY2020 | Dec 31, 2020 | $5.85M | +15.3% |
| FY2019 | Dec 31, 2019 | $5.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.38M | -20.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.62M | -16.9% |
| Q4 FY2025 | Dec 31, 2025 | $4.54M | -12.8% |
| Q3 FY2025 | Sep 30, 2025 | $4.68M | -5.7% |
| Q2 FY2025 | Jun 30, 2025 | $5.50M | +6.6% |
| Q1 FY2025 | Mar 31, 2025 | $5.56M | +5.8% |
| Q4 FY2024 | Dec 31, 2024 | $5.21M | +25.5% |
| Q3 FY2024 | Sep 30, 2024 | $4.96M | +14.1% |
| Q2 FY2024 | Jun 30, 2024 | $5.16M | +46.3% |
| Q1 FY2024 | Mar 31, 2024 | $5.26M | +54.1% |
| Q4 FY2023 | Dec 31, 2023 | $4.15M | +10.7% |
| Q3 FY2023 | Sep 30, 2023 | $4.35M | +14.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.53M | +18.2% |
| Q1 FY2023 | Mar 31, 2023 | $3.41M | +11.8% |
| Q4 FY2022 | Dec 31, 2022 | $3.75M | +11.0% |
| Q3 FY2022 | Sep 30, 2022 | $3.80M | +49.7% |
| Q2 FY2022 | Jun 30, 2022 | $2.98M | +23.2% |
| Q1 FY2022 | Mar 31, 2022 | $3.05M | +63.4% |
| Q4 FY2021 | Dec 31, 2021 | $3.38M | +75.7% |
| Q3 FY2021 | Sep 30, 2021 | $2.54M | +67.9% |
| Q2 FY2021 | Jun 30, 2021 | $2.42M | +146.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.87M | +30.4% |
| Q4 FY2020 | Dec 31, 2020 | $1.92M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.51M | – |
| Q2 FY2020 | Jun 30, 2020 | $982.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $1.43M | – |
See a number that looks wrong?